

REMARKS

Claims 1-22 are pending. No amendments have been made by way of the present submission, thus, no new matter has been added.

In the outstanding Office Action the Examiner has required Applicants to elect one of the following six groups pursuant to Unity of Invention Requirements:

Group I, claims 1-4, drawn to a target protein;

Group II, claims 5-8, drawn to a gene encoding a target protein;

Group III, claims 9-12, drawn to a screening method for an antidiabetic;

Group IV, claims 13, drawn to an antidiabetic compound of undefined structure;

Group V, claims 14-21, drawn to a thiazolidine derivative; and

Group VI, claim 22, drawn to a process for manufacturing a thiazolidine derivative.

Applicants respectfully elect Group III, directed to claims 9-12. This is an election without traverse.

In view of the above, favorable action on the merits is respectfully solicited.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Gerald M. Murphy, Jr., Registration No 28,977 at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.


Application No.: 10/569,791

Docket No.: 1254-0305PUS1

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: November 8, 2007

Respectfully submitted,

By  #47-874
Gerald M. Murphy, Jr.
Registration No.: 28,977
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant